In wet granulation suites handling 8 mg immediate-release thiocolchicoside tablets, the API is first passed through a 500 µm conical sieve to break soft agglomerates before being blended with lactose monohydrate and maize starch in a bin blender of 600 L working capacity. Granulation is performed in a high-shear mixer with impeller speed 150–250 rpm and chopper speed 1,500–2,500 rpm; purified water containing povidone K30 at 2–4% w/w is sprayed at 0.5–1.0 kg/min until wet mass torque reaches 1.2–1.6 N·m. The granulate is dried in a fluid bed dryer with inlet air temperature 55–65°C to a final loss-on-drying of 1.5–2.5% by Ph.Eur. 2.2.32, then dry-sieved through an 800 µm screen. Extragranular croscarmellose sodium at 2–4% w/w and sodium stearyl fumarate at 0.5–1.0% w/w are added before compression on a rotary tablet press with 10.5 mm round biconvex tooling running at 60,000–120,000 tablets/h. Tablet hardness is maintained at 50–80 N per Ph.Eur. 2.9.8, friability below 0.5% per Ph.Eur. 2.9.7, and disintegration time below 15 min per Ph.Eur. 2.9.1. Dissolution is tested in 900 mL of 0.1 M hydrochloric acid at 37 ± 0.5°C using paddle apparatus at 50 rpm per Ph.Eur. 2.9.3, with a routine release specification of not less than 80% released at 30 min. Final film coating with a ready-to-disperse ethylcellulose-free coating system at 3% weight gain is applied in a side-vented pan at exhaust temperature 45–55°C; coating does not alter the dissolution profile when core tablet hardness is held above the lower boundary. Finished 8 mg tablets are packaged in PVC/PVDC/aluminium blister, and stability is evaluated under ICH Q1A(R2) Zone IVb conditions. Formulators avoid peroxide-contaminated povidone and crospovidone batches because the thiomethyl ether in thiocolchicoside can undergo oxidation; excipient peroxide levels are screened against monograph limits and forced degradation data before batch release.

How Does Direct Compression Handle Unit Dose Uniformity at 4 mg Potency?

Direct compression of 4 mg thiocolchicoside tablets is a low-viability route if API particle size is not controlled; the process therefore employs ordered mixing rather than simple dry blending in free-fall mixers. A typical batch is prepared by first blending micronised API with a coarse carrier such as spray-dried lactose monohydrate having D50 100–150 µm in a 1:10 preblend, then extending to final fill weight with microcrystalline cellulose PH-102 and pregelatinised starch. The API fraction is diluted geometrically in a 600 L IBC blender at 12 rpm for 20 min, with sampling at 10 positions to verify relative standard deviation below 5.0% before lubrication. Magnesium stearate is added at 0.5–0.75% w/w and blended for 3 min; excessive lubrication is avoided because interparticulate bonding strength falls sharply above 1.0% w/w. Tablets are compressed on a rotary press equipped with gravity feeder and 8 mm flat-faced bevel tooling; compression force is set between 8 kN and 12 kN to achieve hardness 40–70 N without extending disintegration time. Content uniformity is evaluated per Ph.Eur. 2.9.40, with acceptance value not exceeding 15 for 10 dosage units; when acceptance value exceeds 15, root cause is traced to API agglomeration, carrier segregation, or inadequate preblending. Dissolution is run in 900 mL of phosphate buffer pH 6.8 at 50 rpm using paddle apparatus, with a specification of not less than 80% released in 30 min under Ph.Eur. 2.9.3. Direct compression avoids aqueous granulation and is selected for formulations where the glucosidic linkage in thiocolchicoside may undergo acid-catalysed hydrolysis in the presence of citrate buffers or hygroscopic excipients; pH is therefore maintained above 4.0 in any preblend containing organic acids. The process demands controlled storage humidity of RH ≤ 40% and forced feeder speed optimisation to prevent component segregation on extended runs exceeding 4 h.

Roller-Compacted Granulate Reduces Aqueous Degradation in Hard Gelatin Capsule Fills

The decision to roller compact a thiocolchicoside capsule formulation is driven by poor API powder flow and the need to avoid wet massing of the glucosidic ether. In this route, API is dry blended with microcrystalline cellulose, lactose monohydrate, crospovidone, and colloidal silicon dioxide, then compacted on a roller compactor with 100 mm roll width, roll gap 2.0–3.0 mm, specific compaction force 6–10 kN/cm, and roll speed 12–18 rpm. Ribbon density is targeted at 1.05–1.25 g/cm³; lower density produces excessive fines, while higher density causes granule hardening that delays dissolution. Milling through a 1.0 mm screen with an oscillating granulator yields granule size distribution with D50 200–400 µm and fines below 15% w/w. Powder flow is confirmed by Ph.Eur. 2.9.36, with orifice diameter of 6 mm or Carr index below 20%. The granulate is filled into size 1 hard gelatin capsules at 80,000 capsules/h on a dosator-type capsule filler, with fill weight 180 ± 5 mg for 8 mg thiocolchicoside. Capsules are tested for weight uniformity per Ph.Eur. 2.9.5, dissolution per Ph.Eur. 2.9.3 in 900 mL of 0.1 M hydrochloric acid, and content uniformity per Ph.Eur. 2.9.40. Capsule fill moisture is held below 3.0% because hard gelatin shell brittleness increases below 10% RH and shell crosslinking accelerates above 50% RH. Roller compaction is preferred over wet granulation when the formulation contains a superdisintegrant sensitive to hydration or when the API is diluted below 5% w/w, because it minimises thermal and moisture exposure. The finished capsule is packaged in cold-form aluminium blister providing moisture vapour transmission rate below 0.1 mg/day/package under 40°C/75% RH; qualification is conducted per ICH Q1A(R2) for Zone IVb.

Clinically, single-dose thiocolchicoside granules are dispensed as 4 mg or 8 mg sachets for oral suspension in patients with dysphagia or where tablet splitting introduces dose inaccuracy. The granulate is produced in a top-spray fluidised bed coater with Wurster insert; API and mannitol are loaded, and an aqueous solution containing maltodextrin and sucralose is sprayed at 6–10 g/min/kg of substrate to achieve granules with D50 350–600 µm. Taste masking is achieved by coating the active granules with a methacrylate copolymer dispersion; the polymer coat is applied to 8–12% weight gain, and in vitro release in 0.1 M hydrochloric acid is monitored to ensure no more than 20% of the API is released at 15 min while not less than 80% is released at 60 min. The granules are dried to loss-on-drying below 2.0% and sieved through 800 µm. Filling into sachets is performed on a form-fill-seal machine with laminated aluminium foil; seal integrity is verified according to ASTM F88/F88M-21, and residual oxygen below 2% is maintained by nitrogen flushing. Uniformity of mass of filled sachets is tested per Ph.Eur. 2.9.5, with acceptance limits of ± 5% for individual sachets. The oral suspension prepared by dispersing one sachet in 20 mL of water passes a 710 µm sieve without residue, and the API remains chemically stable for at least 24 h after reconstitution at 2–8°C when protected from light. The single-dose granule format removes the need for tablet coating and tablet press scale-up, but transfers complexity to aerodynamic classification and humidity control; granulation and packaging areas are maintained at 20–25°C and RH ≤ 35% to prevent tacking of the methacrylate film.

When Aqueous Injection Lines Replace Solid Dose for Acute Musculoskeletal Spasm

Aqueous injection lines for thiocolchicoside operate under aseptic conditions because the glucosidic ether and thiomethyl ether moieties may undergo hydrolytic degradation under terminal steam sterilisation cycles above 121°C. The solution is prepared at 2 mg/mL in Water for Injections, with sodium chloride added to isotonicity at 0.85–0.95% w/v; pH is adjusted to 4.5–6.0 using dilute hydrochloric acid or sodium hydroxide. The bulk solution is sparged with nitrogen to reduce dissolved oxygen below 1 ppm, then filtered sequentially through 0.45 µm and 0.22 µm sterilising-grade polyethersulfone filters; filter integrity is tested by bubble point or water intrusion according to the filter manufacturer’s validated method, with bacterial retention validation per ASTM F838-20. Filling is performed on a vial or ampoule line at 2 mL or 4 mL fill volume in an isolator rated ISO 14644-1 class 5, with glass ampoules washed and depyrogenated at 320°C for at least 5 min in a depyrogenation tunnel. Filled ampoules are sealed by flame sealing and inspected for visible particles under Ph.Eur. 2.9.20; rejected containers are removed at the automatic inspection station. Endotoxin level is controlled below 0.5 EU/mL by depyrogenation and validated hold times; the finished product is tested for sterility by membrane filtration per Ph.Eur. 2.6.1 and for bacterial endotoxins per Ph.Eur. 2.6.14. Injectables of thiocolchicoside are administered intramuscularly or intravenously, and the aqueous formulation must remain free of benzyl alcohol if intended for paediatric use; if a preservative is required for multi-dose vials, the maximum concentration is justified by toxicological data and paediatric labelling restrictions. If forced degradation studies show oxidative sensitivity, sodium metabisulfite is added at 0.1% w/v; sulfite sensitivity of the patient population is declared on the packaging. The manufacturing train is validated for media fills with a target contamination rate below 0.1% per EU GMP Annex 1. Because the API is light-sensitive, primary packaging uses amber glass; stability studies per ICH Q1A(R2) include 25°C/60% RH and 2–8°C storage conditions, with pH and related substances monitored as critical quality attributes.

Where the aqueous solution exhibits insufficient long-term hydrolysis control at ambient storage, a lyophilised thiocolchicoside presentation is substituted. The formulation typically contains thiocolchicoside 4 mg/mL before freeze-drying with mannitol or glycine as bulk-forming agent at 3–5% w/v and, if necessary, a phosphate or citrate buffer of 10–20 mM; published data for this specific configuration is limited, so buffer species and concentration are selected from forced degradation studies rather than extrapolated from solid oral forms. The solution is filtered through a 0.22 µm sterilising filter and filled into 5 mL or 10 mL type I borosilicate glass vials with an elastomeric closure. Lyophilisation is performed in a shelf freeze dryer with shelf temperature equilibrated at -45°C for 2 h, primary drying at -10°C and 0.2 mbar for 18–24 h, and secondary drying at 25°C for 4–6 h; the resulting cake has residual moisture below 2.0% by Karl Fischer titration. The reconstitution diluent is Water for Injections or 0.9% w/v sodium chloride; reconstitution time is below 2 min with gentle swirling, and the reconstituted solution must pass clarity and particulate tests per Ph.Eur. 2.9.20. The lyophilised injection is tested for dose uniformity per Ph.Eur. 2.9.40, sterility per Ph.Eur. 2.6.1, and bacterial endotoxins per Ph.Eur. 2.6.14. Storage conditions are set at 2–8°C; freeze-thaw cycling during transport is evaluated using a three-cycle study from -20°C to 25°C. This presentation shifts the operational boundary from sterility assurance of aqueous fill to cake collapse temperature control; collapse temperature is measured by freeze-drying microscopy, and shelf temperature during primary drying must remain below the collapse temperature to avoid macrovoid formation. If the API is co-lyophilised with mannitol, the mannitol crystal form is controlled because amorphous mannitol can recrystallise during storage and release bound water, accelerating hydrolysis of the glucosidic ether.